证券日报网讯 2月6日，新华医疗发布公告称，公司于2024年12月30日召开第十一届董事会第十六次会 议审议通过了《关于现金收购武汉中帜生物科技股份有限公司36.1913%股权的议案》，公司拟收购武 汉中帜生物科技股份有限公司（简称"中帜生物"）36.1913%的股权（简称"标的股份"）。自签订《股份 转让协议》以来，公司积极与交易对方就收购事项履行相关审批程序。截至本公告之日，《股份转让协 议》约定的交割期限已过，经与交易各方友好协商，决定终止《股份转让协议》。公司与深圳市美健电 子科技发展有限公司、深圳市美康信息科技发展有限公司、丁野青、王占宝达成一致意见并签订了《股 份转让协议之补充协议》，同时向上海盛宇黑科创业投资中心（有限合伙）、深圳喜朋私募股权投资基 金合伙企业（有限合伙）、连庆明、庄金辉、董燕、刘卫兵发送了《股份转让协议终止通知函》，终止 此次收购事项。未来，在市场拓展、技术研发等领域，各方将继续保持开放协作的态度，共谋发展机 遇。 （文章来源：证券日报） ...

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

格隆汇2月6日丨新华医疗(600587.SH)公布，自签订《股份转让协议》以来，公司积极与交易对方就收 购事项履行相关审批程序。截至本公告之日，《股份转让协议》约定的交割期限已过，经与交易各方友 好协商，决定终止《股份转让协议》。公司与深圳市美健电子科技发展有限公司、深圳市美康信息科技 发展有限公司、丁野青、王占宝达成一致意见并签订了《股份转让协议之补充协议》，同时向上海盛宇 黑科创业投资中心（有限合伙）、深圳喜朋私募股权投资基金合伙企业（有限合伙）、连庆明、庄金 辉、董燕、刘卫兵发送了《股份转让协议终止通知函》，终止此次收购事项。未来，在市场拓展、技术 研发等领域，各方将继续保持开放协作的态度，共谋发展机遇。 ...

二、终止股权收购的原因 证券代码：600587 证券简称：新华医疗 公告编号：临 2026-009 山东新华医疗器械股份有限公司 关于终止收购武汉中帜生物科技股份有限公司 36.1913%股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、交易情况概述 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于 2024 年 12 月 30 日召开第十一届董事会第十六次会议审议通过了《关于现金收购武汉中 帜生物科技股份有限公司 36.1913%股权的议案》，公司拟收购武汉中帜生物科技 股份有限公司（以下简称"中帜生物"）36.1913%的股权（以下简称"标的股份"）， 详见公司于 2024 年 12 月 31 日在上海证券交易所网站（www.sse.com.cn ）披露的《新华医疗第十一届董事会第十六次会议决议公告》（公告编号：临 2024-043）、《新华医疗关于收购武汉中帜生物科技股份有限公司 36.1913%股权 的公告》（公告编号：临 2024-045）。 自签订《股份转让协议》以来，公司积极与 ...

新华医疗公告称，公司原拟收购中帜生物36.1913%股权，于2024年12月30日通过相关议案。截至公告 日，《股份转让协议》约定的交割期限已过，经协商决定终止该协议。公司与部分交易对方签订《股份 转让协议之补充协议》，并向其他方发送《股份转让协议终止通知函》。因付款先决条件未达成，公司 未付款，收购终止不会对现有经营业绩及财务状况产生不利影响。 ...

Core Viewpoint - Xinhua Medical (600587) has experienced a decline in both revenue and net profit for the first three quarters of 2025, indicating potential challenges in its business performance [1] Financial Performance - For the first three quarters of 2025, Xinhua Medical reported a main revenue of 6.978 billion yuan, a year-on-year decrease of 6.0% [1] - The net profit attributable to shareholders was 434 million yuan, down 29.61% year-on-year [1] - The non-recurring net profit was 370 million yuan, reflecting a decline of 38.98% year-on-year [1] - In Q3 2025, the company recorded a single-quarter main revenue of 2.188 billion yuan, a decrease of 2.2% year-on-year [1] - The single-quarter net profit attributable to shareholders was 48.59 million yuan, down 63.39% year-on-year [1] - The single-quarter non-recurring net profit was 37.66 million yuan, a decline of 71.77% year-on-year [1] - The company's debt ratio stands at 45.85%, with investment income of 48.28 million yuan and financial expenses of 21.30 million yuan [1] - The gross profit margin is reported at 25.11% [1] Market Activity - As of February 5, 2026, Xinhua Medical's stock closed at 15.45 yuan, down 0.58% with a turnover rate of 0.96% [1] - The trading volume was 57,800 hands, with a total transaction amount of 89.46 million yuan [1] - On February 5, the net inflow of main funds was 563,100 yuan, accounting for 0.63% of the total transaction amount [1] - The net inflow of speculative funds was 2.8369 million yuan, representing 3.17% of the total transaction amount [1] - Retail investors experienced a net outflow of 3.4001 million yuan, which is 3.8% of the total transaction amount [1] Analyst Ratings - In the last 90 days, two institutions have given ratings for Xinhua Medical, both recommending an increase in holdings [2] - The average target price set by institutions in the past 90 days is 20.0 yuan [2]

证券代码：600587 证券简称：新华医疗 公告编号：临2026-008 山东新华医疗器械股份有限公司关于子公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）全资子公司新华医疗康复产业（西 安）有限公司于近日收到陕西省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况 如下： 一、医疗器械注册证的具体情况 1、产品名称：四肢联动康复训练仪 2、注册证编号：陕械注准20262190001 3、注册人名称：新华医疗康复产业（西安）有限公司 4、注册人住所：陕西省西安市国际港务区港务大道99号中西部陆港金融小镇F座1901号 8、适用范围：适用于辅助提高四肢的肌力及协调性，改善关节活动度。 9、批准日期：2026-01-23 10、有效期至：2031-01-22 11、同类产品相关情况：根据国家药品监督管理局官网数据查询信息，截至目前，国内同行业有18家公 司已取得同类产品的医疗器械注册证。 12、产品主要特点 基于机 ...

Buybacks and Shareholder Actions - Guizhou Moutai has repurchased a total of 416,900 shares, accounting for 0.0333% of its total share capital, with a total payment of 571 million yuan [1] - Contemporary Amperex Technology Co., Ltd. has repurchased 15,990,800 shares, representing 0.3628% of its total A-share capital, with a total transaction amount of 4.386 billion yuan [2] - SF Holding has repurchased 5,095,850 shares, which is 1.01% of its total share capital, with a total amount of approximately 2 billion yuan [10] - Wireless Media has seen its major shareholders reduce their stakes, with Wensheng Fund and its concerted parties reducing 4% of the total share capital [12] Corporate Actions and Financial Updates - Tai Ling Microelectronics announced that its second-largest shareholder, the National Integrated Circuit Industry Investment Fund, has reduced its stake from 6.95% to 5.97% by selling 2,321,300 shares [3] - Nape Mining has terminated its investment in Swiss Veritas Resources AG due to changes in delivery conditions, with no breach of contract [4] - Huangshan Tourism plans to invest approximately 530 million yuan in the construction of a hotel project, with a total building area of 79,178.15 square meters [8][9] - *ST Jinling's restructuring plan has been approved by the court, allowing the company to enter the execution phase of the plan [7] Performance and Sales - Country Garden reported a contract sales amount of approximately 2.21 billion yuan for January 2026, with a sales area of about 280,000 square meters [11] - Industrial Fulian has accumulated a total buyback fund of 247 million yuan as of January 31, 2026 [17] - Yutong Bus produced 2,167 vehicles in January 2026, a decrease of 15.35% year-on-year [17]

Group 1 - Fulin Precision's subsidiary Jiangxi Shenghua invested 270 million yuan to establish a joint venture for a 500,000-ton ferrous oxalate project, with a total investment of 1.5 billion yuan expected to be completed by September 30, 2026 [1] - Xuguang Electronics plans to raise up to 1 billion yuan through a private placement to fund high-voltage vacuum arc extinguishing chamber expansion and other projects [2] - Minexplosion Optoelectronics intends to acquire 100% equity of Xiazhi Precision, with the transaction subject to shareholder and regulatory approvals [3] Group 2 - Shangluo Electronics' controlling shareholder plans to reduce his stake by up to 3% due to personal financial needs [4] - Babi Food reported a 1.3% decline in net profit for 2025, despite an 11.22% increase in revenue [5] - Pengding Holdings' subsidiary acquired industrial land in Huai'an for 66.14 million yuan [6] Group 3 - Zhuoyue New Energy's net profit for 2025 increased by 14.16%, despite a 17.43% decline in revenue [7] - Zhongyuan Media's net profit grew by 30.99% in 2025, with revenue decreasing by 5.13% [8] - Huangshan Tourism plans to invest approximately 530 million yuan in a hotel project with a 24-month construction period [9] Group 4 - *ST Jinling's restructuring plan was approved by the court, which may improve the company's financial situation [11] - Jichuan Pharmaceutical's subsidiary paid 80 million yuan for exclusive commercialization rights of a drug [12] - Pilin Bio's subsidiary received a notice for the acceptance of a drug supplement application [13] Group 5 - Nepe Mining terminated its investment in Swiss Veritas Resources AG due to changes in conditions [14] - Jinhui Wine announced a cash dividend of 0.20 yuan per share for the first three quarters of 2025 [15] - Hualan Biological's clinical trial for a new drug received approval for an additional indication [16] Group 6 - Industrial Fulian reported a total of 247 million yuan spent on share buybacks as of January 31, 2026 [17] - Yitong Century was pre-selected for a 107 million yuan project with China Tower [18] - Wanfeng Co. noted uncertainty in future price changes for disperse dyes [19] Group 7 - Bibet's clinical trial application for a new drug was approved by the National Medical Products Administration [21] - Chengbang Co. signed new project contracts worth 40.03 million yuan in Q4 2025 [22] - *ST Hengji received a court ruling for a performance compensation of 175 million yuan [23] Group 8 - Jihua Group is planning a change in control, leading to continued stock suspension [24] - Ningbo Port expects a container throughput of 5.03 million TEUs in January 2026, a 9.5% increase [25] - Hengli Petrochemical's actual controller increased his stake by 3.3 million shares [26] Group 9 - Hongfuhan signed a sales contract worth 480 million yuan with Guangdong Quanxiang [27] - All New Good's shareholder lifted a judicial freeze on 4.36% of the company's shares [28] - Changchun High-tech's subsidiary's clinical trial application for a new drug was accepted [29] Group 10 - Xingqi Eye Medicine's clinical trial for a new drug entered the first/second phase [31] - Hanma Technology reported a 140.04% increase in new energy heavy truck production in January 2026 [32] - Hengfeng Paper plans to invest 349 million yuan in a new green printing project [33] Group 11 - Zhifei Biological's mRNA vaccine for shingles received clinical trial approval [34] - Yutong Bus reported a 15.35% decrease in production in January 2026 [35] - StarNet Ruijie plans to sign a lease contract with an affiliate for a total rent of up to 110 million yuan [36] Group 12 - Hacheng Bonda's director completed a 0.97% share reduction [37] - Hendi Pharmaceutical's application for a new drug was approved [38] - Xinhua Medical's subsidiary received a medical device registration certificate [40] Group 13 - Yaokang Bio reported a 31.49% increase in net profit for 2025 [41] - Gaotie Electric reported a 14.02% increase in net profit for 2025 [42]

山东新华医疗器械股份有限公司 关于子公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）全资子 公司新华医疗康复产业（西安）有限公司于近日收到陕西省药品监督管理局颁发的 《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：四肢联动康复训练仪 2、注册证编号：陕械注准 20262190001 3、注册人名称：新华医疗康复产业（西安）有限公司 证券代码：600587 证券简称：新华医疗 公告编号：临 2026-008 9、批准日期：2026-01-23 10、有效期至：2031-01-22 11、同类产品相关情况：根据国家药品监督管理局官网数据查询信息，截至目 前，国内同行业有 18 家公司已取得同类产品的医疗器械注册证。 12、产品主要特点 基于机械机构将扶手和脚踏的运动实现联动，使四肢中仅靠一侧健肢的运动即 可带动四肢同步运动，从而辅助提高偏瘫、骨关节损伤等患者四肢的肌力、关节活 动度 ...